Nanofibre scale-up and industrial validation - Industrial Biotechnology Catalyst Translation and Industrial Research Awards

生物制药是制药行业中越来越重要的一个部门，目前正在开发的所有药物中有三分之一以上是生物制药，它们占据了前十大收入重磅产品的一半。开发一种新药通常需要10年以上的时间和8亿美元的资金。全球对廉价生物治疗药物的需求推动了降低制造成本的需求，这些药物代表了对抗癌症和神经退行性疾病等疾病的许多新工具。目前用于确保这些治疗的安全性和有效性的净化技术所产生的成本占目前成本的很大一部分。这个项目的目标是建立在拥有新型纳米纤维净化技术的中小企业purify和世界领先的工业生物处理技术开发研究机构伦敦大学学院（UCL）之间现有合作的基础上。该项目由purify领导并得到影子工业合作伙伴的支持，该项目的成功授予将见证创新生物处理平台技术的开发和商业化，从而使各种现有产品和新产品的生产具有成本效益。该项目将加速purpurify的新型平台下游生物处理技术的商业化发展。提高生产力的技术将为新产品和现有产品提供有效的制造途径，通过降低成本和使下一代生物治疗药物的经济制造成为可能，从而造福社会和整个行业。利用新的加工技术、理论和模型，这个综合的工业研究和发展项目将通过汇集英国工业生物技术社区的关键学术和商业组成部分，加速这项技术的商业化。

Biopharmaceuticals are an increasingly important sector of the pharmaceutical industry, over one third of all drugs now in development are biopharmaceuticals and they make up half of the top 10 revenue blockbusters. It typically takes over 10 years and $800 million to develop a new drug. Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. This project aims to build on existing collaborations between Puridify, an SME with a novel nanofibre purification technology, and University College London (UCL), a world leading research organisation for the development of industrial bioprocessing technologies. The successful award of this project lead by Puridify and supported by shadow industrial partners will see the development and commercialisation of innovative bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new products.The project will accelerate development of Puridify's novel platform downstream bioprocessing technologies towards commercial activity. The technologies increased productivity will provide an efficient manufacturing route to both new and existing products benefiting society and the sector as a whole by reducing costs and enabling the economic manufacture of next generation biotherapeutics. Using new processing technologies, theory and modelling, this integrated Industrial Research and Development project will accelerate the commercialisation of this technology by bringing together key academic and business components of the UK Industrial Biotechnology community.